Brief: Vallon Streamlines Operations To Preserve Capital, Cash Resources
April 22 (Reuters) - Vallon Pharmaceuticals Inc VLON.O :
* VALLON PHARMACEUTICALS ANNOUNCES REVIEW OF STRATEGIC
ALTERNATIVES
* VALLON PHARMACEUTICALS INC - ENGAGED LADENBURG THALMANN &
CO.
INC. ("LADENBURG") TO EVALUATE STRATEGIC ALTERNATIVES FOR
COMPANY
* VALLON PHARMACEUTICALS INC - STREAMLINING ITS OPERATIONS
IN
ORDER TO PRESERVE ITS CAPITAL AND CASH RESOURCES
Source text for Eikon: ID:nGNX3JVDbv
Further company coverage: VLON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027